Related by context. All words. (Click for frequent words.) 82 Phase IIb 79 Phase 2a 78 Phase III 77 Phase 2b study 77 Phase 2b clinical 77 Phase IIb clinical 76 Phase III clinical 76 pivotal Phase III 76 Phase 2b trial 76 Phase 1b 75 phase IIb 75 Phase Ib 75 Phase IIa 75 phase IIa 75 Phase 2a clinical 74 phase IIb clinical 74 Phase IIa trial 74 phase IIa clinical 73 pivotal Phase 73 Phase IIb trial 73 phase 2a 73 Phase 2a trial 73 Phase IIa clinical 73 Phase Ib clinical 72 Phase 1b clinical 72 placebo controlled Phase 72 Phase II 71 Phase 1a 70 Phase 1b trial 70 Phase III pivotal 70 dose escalation Phase 69 randomized Phase 69 Phase III trials 69 phase IIb trial 69 dose escalation trial 69 Phase IIa trials 69 Phase Ia 68 Phase III clinical trials 68 Phase Ib II 67 Phase IIIb clinical 67 Phase IIIb 67 phase Ib 67 randomized Phase III 67 randomized controlled Phase 67 registrational trial 67 multicenter Phase 67 confirmatory Phase III 67 Phase IIb trials 67 multiple ascending dose 67 APEX PD 66 PRX # 66 Phase 66 Phase 2b clinical trials 66 BRIM3 66 Phase 1a clinical 66 registrational 66 confirmatory Phase 3 66 SUCCEED trial 66 Phase Ib study 66 Phase IIB 66 Amrubicin 66 multicenter Phase II 65 Phase #b/#a 65 elotuzumab 65 placebo controlled clinical 65 INCB# [002] 65 randomized Phase 2b 65 NO# [002] 65 BRIM2 65 phase IIb study 65 alvespimycin 65 randomized Phase IIb 65 ongoing Phase 1b 64 placebo controlled 64 GALNS 64 celgosivir 64 TMC# C# 64 PSN# [002] 64 TMC# [002] 64 LUX Lung 64 JAK inhibitor 64 deforolimus 64 oral ridaforolimus 64 blind randomized placebo 64 dirucotide 64 clinical trial 64 MEND CABG 64 APPRAISE 64 Dacogen injection 64 PS# [001] 64 Pivotal Phase 64 Phase III Clinical Trial 64 placebo controlled Phase III 64 blinded randomized placebo controlled 64 multicenter Phase III 64 double blinded placebo 64 dose escalation study 64 Phase III placebo controlled 63 multicenter phase 63 Phase IIb clinical trials 63 Phase 1b dose escalation 63 Phase IIa clinical trials 63 teduglutide 63 lomitapide 63 randomized multicenter 63 bicifadine 63 ularitide 63 FOLOTYN ® 63 randomized placebo controlled 63 Initiated Phase 63 dose cohorts 63 AP# [003] 63 Phase III randomized controlled 63 Augment Injectable 63 Phase #/#a 63 ISIS # 63 axitinib 63 multicenter clinical 63 Pivotal Phase III 63 multicenter 63 Initiate Phase 63 Mipomersen 63 ozarelix 63 PRECiSE 63 ADVANCE PD 63 Randomized Phase 63 double blind placebo 62 forodesine 62 KRN# 62 dose escalation clinical 62 obatoclax 62 Elagolix 62 blinatumomab 62 MGCD# [001] 62 INCB# [001] 62 multicenter randomized Phase 62 pharmacokinetic PK 62 glufosfamide 62 omacetaxine mepesuccinate 62 Pivotal Trial 62 multicenter randomized placebo controlled 62 EOquin TM 62 Cloretazine R VNP#M 62 MAA submission 62 Phase IIb Trial 62 treatment naïve genotype 62 elagolix 62 Archexin 62 Azedra 62 Cloretazine ® 62 CR# vcMMAE 62 sapacitabine 62 Zenvia Phase III 62 TG MV 62 Phase III psoriasis 62 Plicera 62 ganetespib 62 COMFORT II 62 ENDEAVOR IV 62 PXD# 62 SCH # 62 enzastaurin 62 phase Ib clinical 62 TASKi2 62 docetaxel Taxotere R 62 dose escalation 61 multicenter randomized double 61 BCX# 61 phase IIIb 61 multicenter randomized 61 tolerability 61 Perifosine 61 oral prodrug 61 velafermin 61 HuMax EGFr 61 ARRY 61 Phase 2b Clinical Trial 61 IMA# 61 Traficet EN 61 tanespimycin 61 multicentre randomized 61 Phase III Clinical Trials 61 preclinical 61 investigational compound 61 PRT# 61 pharmacokinetic PK study 61 placebo controlled randomized 61 CRx 61 phase IIb III 61 sunitinib malate 61 HCV SPRINT 61 RDEA# 61 OncoVEX GM CSF 61 AEGR 61 HCV protease inhibitor 61 PREOS 61 NGX# 61 PRE SURGE 61 DDP# 61 Phase Ib clinical trials 61 Phase 2b monotherapy 61 LUMINATE 61 XL# [003] 61 selective androgen receptor modulator 61 masked placebo controlled 61 ASA# 61 AeroLEF TM 61 denufosol 61 mipomersen 61 EOquin 61 Phase #/#a trial 61 alvimopan 61 albinterferon alfa 2b 61 randomized double 61 assessing T DM1 61 ofatumumab 61 HGS# 61 HGS ETR1 61 pharmacokinetics PK 61 trodusquemine 61 relapsed refractory multiple myeloma 61 Ostarine 60 Phase III randomized 60 AEZS 60 PEG Interferon lambda 60 BAY #-# 60 R#/MEM # 60 label multicenter 60 virus HCV protease inhibitor 60 SYMMETRY trial 60 AQ4N 60 Pivotal Study 60 Tyrima 60 ascending dose 60 vidofludimus 60 resminostat 60 mGluR5 negative 60 viral kinetic 60 dyskinesia PD LID 60 PEG PAL 60 brivaracetam 60 PEG SN# 60 diabetic neuropathic pain 60 clinical pharmacology studies 60 Phase 2a clinical trials 60 IND enabling 60 afatinib 60 IIa trial 60 PHX# 60 Oglemilast 60 QLT# 60 GLP toxicology studies 60 CRLX# 60 fostamatinib 60 pharmacokinetic studies 60 cetrorelix 60 trastuzumab emtansine T DM1 60 lubiprostone 60 pivotal bioequivalence 60 TBC# 60 investigational humanized monoclonal antibody 60 compound INCB# 60 Locteron ® 60 elacytarabine 60 midstage trials 60 rALLy clinical trial 60 Phase 2b kidney transplant 60 SABCS 60 RG# [001] 60 Phase Ib IIa 60 rNAPc2 60 Phase #b/#a clinical 60 cannabinor 60 HuMax CD4 60 ThermoDox R 60 AEG# 60 Zerenex 60 receptor tyrosine kinase inhibitor 60 TASQ 60 AVADO 60 nab paclitaxel 60 IMGN# 60 eniluracil 60 ascending doses 60 Phase 2b randomized 60 vascular disrupting agent 60 dosing cohorts 60 Exherin TM 60 L BLP# 60 Phase III Trial 60 crizotinib PF # 60 initiate Phase IIb 60 Carfilzomib 60 AZILECT R 60 lixisenatide 60 ADX# 60 GetGoal Phase III 60 lumiliximab 60 Aurexis 60 clinical trials 60 Ozarelix 60 Urocidin 60 single ascending dose 60 Alocrest 60 nitazoxanide 60 treatment naive genotype 60 phase III ACCLAIM 60 ThermoDox ® 60 ATL# [001] 60 Phase IIb kidney transplant 59 II Clinical Trial 59 investigational pan BCR 59 metastatic HRPC 59 preclinical efficacy 59 label multicenter Phase 59 prospective randomized placebo 59 GATTEX TM 59 HER2 positive metastatic breast 59 blind randomized 59 Bezielle 59 EVEREST II 59 lorcaserin Phase 59 budesonide foam 59 PROSTVAC TM 59 opioid induced bowel dysfunction 59 HspE7 59 perifosine 59 initiate Phase 59 Prodarsan 59 stated Michelle Berrey 59 PREOS R 59 Corlux 59 CLARITY study 59 MLN# 59 tesmilifene 59 Guanilib 59 Phenoptin 59 Sapacitabine 59 NP2 Enkephalin 59 Azixa 59 ELACYT 59 Phase IIA 59 confirmatory clinical 59 Fx #A 59 RSD# oral 59 oral deforolimus 59 Sorafenib HCC Assessment 59 IND submission 59 teriflunomide 59 Panzem R NCD 59 Tanespimycin 59 multicenter placebo controlled 59 active comparator 59 EndoTAG TM -1 59 Sym# 59 Investigational Device Exemption IDE 59 controlled multicenter 59 Phase III confirmatory 59 IL# PE#QQR 59 dose cohort 59 edoxaban 59 Amigal 59 Dapagliflozin 59 Shigamabs ® 59 Virulizin ® 59 PRESEPT 59 IIa clinical trial 59 Phase 1b clinical trials 59 Phase IIb III 59 Phase III ALLEGRO 59 riociguat 59 CA4P 59 sNDA submission 59 HCV RESPOND 2 59 tivozanib 59 acyclovir Lauriad R 59 BLA submission 59 EVIZON 59 LymphoStat B TM 59 XL# XL# XL# 59 evaluating tivozanib 59 Alzhemed TM 59 confirmatory Phase 59 Marqibo 59 rALLy trial 59 MBP# [001] 59 Phase 2a Clinical Trial 59 seliciclib CYC# 59 lintuzumab 59 microplasmin 59 Parkinson disease levodopa induced 59 Hsp# Inhibitor 59 talactoferrin 59 LibiGel ® 59 NVA# 59 Brentuximab Vedotin SGN 59 HDAC Inhibitor 59 TRO# 59 prospective multicenter 59 IIa clinical 59 CIMZIA TM 59 LymphoStat B 59 PANVAC VF 59 relapsed multiple myeloma 59 miconazole Lauriad ® 59 Phase III Pivotal 59 metaglidasen 59 Proxinium TM 59 linaclotide 59 TACI Ig 59 Annamycin 59 eprotirome 59 PDE4 inhibitor 59 Ceflatonin R 58 Gabapentin GR 58 TEMSO 58 LCP AtorFen 58 custirsen 58 CEQ# 58 MERLIN TIMI 58 Zybrestat 58 ACAPODENE 58 fosbretabulin 58 Phase IIIb study 58 Ambrisentan 58 Pimavanserin 58 dose dose escalation 58 ZACTIMA 58 aclidinium 58 torezolid phosphate 58 AzaSite Plus 58 neurogenic orthostatic hypotension 58 telaprevir VX 58 Androxal TM 58 APTIVUS 58 ruxolitinib 58 Randomized Phase II 58 valopicitabine 58 rALLy 58 Viramidine 58 Ophena TM 58 prospective randomized controlled 58 Gattex 58 oral rivaroxaban 58 Civacir 58 dirucotide MBP# 58 HGS ETR2 58 romidepsin 58 metastatic hormone refractory 58 LUVENIQ 58 aclidinium bromide 58 ProLindac 58 label multicenter randomized 58 ITAX 58 huN# DM1 58 liposomal formulation 58 prospective randomized 58 AZILECT ® 58 oral calcitonin 58 TRANSFORMS 58 SPIRIT III 58 tramiprosate Alzhemed TM 58 Factor VIIa 58 amrubicin 58 MEK inhibitor 58 IMPACT DCM 58 ILLUMINATE 58 NXL# 58 AZX# Phase 58 Lupuzor 58 Dyloject TM 58 CAMMS# 58 GSK# [002] 58 BIBW 58 ocrelizumab 58 MEK inhibitor RDEA# 58 prospective multicenter randomized 58 Safinamide 58 Omacetaxine 58 Locteron 58 belinostat 58 oral FTY# 58 Daclizumab 58 IMC #B 58 voreloxin 58 eculizumab 58 HZT 58 dosing cohort 58 AACR NCI EORTC 58 Dextofisopam 58 dextromethorphan quinidine 58 ORENCIA ® 58 TAXUS ATLAS 58 Genz # 58 nucleotide analog 58 randomized clinical 58 IMC A# 58 preclinical toxicology 58 GLPG# 58 carfilzomib 58 Clinical Trial Results 58 Cetrorelix 58 Microplasmin 58 SNT MC# 58 label dose escalation 58 mertansine 58 Alpharadin 58 fidaxomicin Phase 3 58 histone deacetylase HDAC inhibitor 58 SPIRIT FIRST 58 satraplatin Phase 58 Phase lll 58 randomized multicentre 58 ixabepilone 58 VNP#M 58 methylnaltrexone 58 regorafenib 58 Aflibercept 58 administered subcutaneously 58 OvaRex ® MAb 58 LibiGel Phase III 58 galiximab 58 PCK# 58 IDX# 58 CUSTOM III 58 PSMA ADC 58 voclosporin 58 Phase 2a Study 58 reslizumab 58 Pirfenidone 58 randomized controlled 58 AKT inhibitor 58 Multiple Ascending Dose 58 European Sepsis Trial 58 telaprevir dosing 58 Panzem R 58 ORAL Sync 58 EGS# 58 OHR/AVR# 58 Meets Primary Endpoint 58 ACTEMRA TM 58 monotherapy 58 Æterna Zentaris 58 neratinib 58 PERSEUS 58 QNEXA 58 Restanza 58 Glufosfamide 58 VEGF Trap 58 Zenvia ™ 58 tamibarotene 58 OvaRex R 58 relapsing multiple sclerosis 58 including eniluracil ADH 58 TLK# 58 LEVADEX 58 huC# DM4 58 PDX pralatrexate 58 fidaxomicin Phase 58 ANCHOR trial 57 Icatibant 57 Triolex 57 OPT CHF 57 novel histone deacetylase 57 GW# [003] 57 BLOOM DM 57 vosaroxin 57 Combination REOLYSIN R 57 Relovair 57 Phase IIb Clinical Trial 57 trastuzumab DM1 T DM1 57 NDA submission 57 Phase III Trials 57 RELOVAIR ™ 57 PRTX 57 novel VDA molecule 57 varespladib 57 Huntexil 57 Telaprevir 57 Tesetaxel 57 pertuzumab 57 davunetide intranasal AL 57 Pharmacokinetics PK 57 Maximum Tolerated Dose 57 Zensana TM 57 initiate Phase 2b 57 pharmacokinetic 57 UPLYSO 57 tezampanel 57 investigational drug 57 Phase III Psoriasis 57 Troxatyl 57 generation purine nucleoside 57 ALD# 57 vicriviroc 57 DASISION 57 double blinded randomized 57 Vicriviroc 57 Phase 2b Study 57 BLA filing 57 Allovectin 7 R 57 Denufosol 57 lorvotuzumab mertansine 57 ZYBRESTAT 57 midstage studies 57 PEP# [003] 57 metastatic sarcomas 57 multicenter prospective 57 allosteric modulator NAM 57 JAK2 inhibitor 57 Phase IIa proof 57 IMPACT IMmunotherapy 57 TH# [003] 57 PA# [002] 57 Harry Palmin President 57 Virulizin R 57 MAP# 57 visilizumab 57 cariprazine 57 BOLDER II 57 evaluating REVLIMID 57 randomized controlled multicenter 57 efficacy endpoint 57 CCX# B 57 prospective randomized multicenter 57 CCX# 57 Glybera R 57 CoFactor 57 hormone refractory prostate cancer 57 Laquinimod 57 Cloretazine 57 ARDIS 57 BrachySil TM 57 rilonacept 57 CLL8 57 Clolar ® 57 ProSavin 57 Quinamed 57 COSIRA trial 57 HRPC 57 multicenter multinational 57 GEM OS1 57 volociximab 57 T DM1 57 XL# SAR# 57 REOLYSIN ® 57 PROMACTA 57 picoplatin 57 ataluren 57 Ceflatonin 57 MEND CABG II 57 ADAGIO study 57 ALKS 57 PLK1 SNALP 57 DURATION 57 TOLAMBA 57 TELCYTA 57 telaprevir dosed 57 subcutaneous formulation 57 FTY# fingolimod 57 IPL# 57 atacicept 57 Prospective Randomized 57 controlled multicenter Phase 57 TPI ASM8 57 Phase 2b Trial 57 Golimumab 57 pradefovir 57 AVN# [001] 57 viral kinetics 57 PEG IFN 57 MIVI III 57 preclinical studies 57 Metastatic Melanoma 57 PFO migraine 57 IMPACT DCM clinical 57 MOZOBIL 57 CB2 selective receptor agonist 57 mapatumumab 57 randomized discontinuation trial 57 Bronchitol 57 refractory gout 57 ToGA 57 CHAMPION PCI 57 AIR CF1 57 thymalfasin 57 Peginterferon 57 Pivotal Clinical Trial 57 candidates Dyloject TM 57 olaparib 57 PS# DARA 57 arzoxifene 57 Xanafide 57 investigational hepatitis C 57 Aclidinium 57 Dacogen decitabine 57 multicentre randomized double 57 safety tolerability 57 palifosfamide 57 Azedra TM 57 apaziquone 57 velafermin belinostat 57 Fibrillex TM 57 Anturol TM 57 FOLOTYN 57 unblinding 57 generation proteasome inhibitor 57 secondary efficacy endpoints 57 eltrombopag 57 recurrent malignant glioma 57 leading oral taxane 57 paclitaxel poliglumex 57 RE SURGE 57 Drug Eluting Stent System 57 Phase #b/#a trial 57 ENDEAVOR III 57 pomalidomide 57 Tarvacin TM 57 Bicifadine 57 PF # [001] 57 atrasentan 57 OLpur TM H2H 57 GAMMAGARD 57 Omigard 57 Defibrotide 57 GATTEX 57 Diabetic Macular Edema 57 REVLIMID lenalidomide 57 CLIRS 57 DermaVir Patch 57 Protease Inhibitor 57 Pazopanib 57 randomized #:# 57 Allovectin 7 ® 56 Aryplase 56 refractory CLL 56 PROPEL 56 midstage clinical 56 Darusentan 56 Aplidin 56 ITMN 56 refractory metastatic colorectal cancer 56 SAR# [004] 56 Hsp# inhibitor 56 Cotara 56 Catena ® 56 BST CarGel R 56 EFAPROXYN 56 Serdaxin 56 unique alkylating agent 56 multicenter randomized controlled 56 ATACAND 56 Study Evaluating 56 bardoxolone 56 bosentan 56 Synavive 56 LEVADEX ™ 56 ganaxolone 56 crofelemer 56 OXi# 56 BEMA Buprenorphine 56 Phase III ThermoDox 56 HuLuc# 56 glatiramer acetate 56 ulimorelin 56 MAXY alpha 56 sodium thiosulfate STS 56 tiapamil 56 symptomatic BPH 56 AMR# 56 NSABP B 56 subanalysis 56 Phase III VISTA 56 Firazyr 56 Randomized Double Blind Placebo 56 initiate Phase 1b 56 Efficacy Results 56 solithromycin 56 MT# MEDI 56 Clavis Pharma 56 ONCONASE 56 laquinimod 56 evaluating mipomersen 56 ACTEMRA 56 Pegasys plus Copegus 56 Rezular 56 FAME Study 56 iniparib 56 daclizumab 56 New Drug Application 56 Phase #/#a clinical 56 depsipeptide 56 prucalopride 56 RE LY ® 56 TASKi3 56 Vernakalant 56 adecatumumab MT# 56 pitavastatin 56 blind randomized controlled 56 MDV# 56 trials RCTs 56 RG# ITMN 56 Glatiramer Acetate 56 Cimzia ® certolizumab pegol 56 tesetaxel 56 CTAP# Capsules 56 Trial Evaluating 56 Acute Ischemic Stroke 56 terlipressin 56 Enobia 56 baminercept 56 BEMA TM Fentanyl 56 Vilazodone 56 mitogen activated ERK kinase 56 lintuzumab SGN 56 NKTR 56 Atu# 56 Luveniq 56 photoprotective drug 56 Clevudine 56 Tovaxin 56 kinase inhibitor 56 Phase III multicenter 56 PrevOnco 56 Successfully Completes Phase 56 cancer neuroendocrine tumor 56 Blinatumomab 56 MIST II 56 YONDELIS 56 SPIRIT IV 56 registrational Phase 56 ALSYMPCA 56 adecatumumab 56 pralatrexate injection 56 SPP# [001] 56 HCV NS5B polymerase 56 RGB # 56 non nucleoside inhibitor 56 Aplidin R 56 ceftaroline 56 Ophena 56 BR.# 56 ZYBRESTAT TM 56 Phase 2a Trial 56 otelixizumab 56 APF# 56 rFVIIIFc 56 BrachySil 56 CYT# 56 orally bioavailable 56 rindopepimut 56 cystinosis patients 56 ELND# 56 Prostate AdenoCarcinoma Treatment 56 BCIRG 56 castrate resistant prostate cancer 56 NLX P# 56 TELINTRA 56 ponatinib 56 LAF# 56 Phase IIB clinical 56 Onco TCS 56 HuMax CD# 56 incyclinide 56 Taxotere ® 56 Serdaxin ® 56 PI3K/Akt pathway inhibitor 56 talabostat 56 ENDEAVOR II 56 angiotensin receptor blocker ARB 56 ONCONASE R 56 investigational compounds 56 pharmacodynamic PD 56 ocular formulation 56 EchoCRT 56 initiate Phase Ib 56 Debio 56 Vicinium TM 56 Q#IR 56 Orazol 56 RSD# 56 Iloperidone 56 ISA# [002] 56 Ereska 56 IRX 2 56 multicentre 56 ALN TTR# 56 polymerase inhibitor 56 OMP #M# 56 Kamada AAT 56 dimebon 56 Vitaxin 56 GOUT 56 ISTODAX ® 56 Phase III HEAT 56 Biologics License Application BLA 56 Valsartan 56 BRAF inhibitor 56 radiation sensitizer 56 castration resistant prostate cancer 56 interferon gamma 1b 56 R# #mg BID 56 First Patient Dosed 56 Tavocept 56 Initiates Phase 56 subcutaneously administered 56 CCR5 antagonist 56 STRIDE PD 56 CONSERV 56 pralatrexate 56 nonclinical studies 56 apremilast 56 VA# [002] 56 AZD# 56 pharmacodynamic 56 clofarabine 56 unblinded 56 Lubiprostone 56 albiglutide 56 leukemia AML 56 Dose Ranging Study 56 Proellex TM 56 initiated Phase Ib 56 STX# 56 interferon beta 1b 56 low dose cytarabine 56 Actilon 56 entinostat 56 cetuximab Erbitux 56 Imprime PGG 55 Pertuzumab 55 bosutinib 55 Achieves Primary Endpoint 55 preclinical pharmacokinetic 55 AZOR 55 tolerability profile 55 ALGRX 55 nucleoside analog 55 SUTENT ® 55 ORACLE MS 55 ICA # 55 Clinical Oncology Annual Meeting 55 R#/MEM 55 blind placebo controlled 55 RE LY 55 Romidepsin 55 ThGRF 55 Epratuzumab 55 HIV integrase inhibitor 55 Phase IIb randomized 55 Evoltra 55 nonrandomized 55 ROCKET AF 55 blinded placebo controlled 55 Nexavar sorafenib 55 SinuNase TM 55 HepeX B TM 55 null responder HCV 55 DU #b 55 aflibercept 55 maximally tolerated dose 55 TKB# 55 bendamustine 55 CIMZIA ™ 55 JZP 55 Exherin 55 pramlintide 55 PROVENGE sipuleucel T 55 advanced metastatic prostate 55 ATL/TV# 55 MAGE A3 ASCI 55 randomized 55 substudy 55 ALN TTR 55 #mg QD [002] 55 ACCLAIM 55 Lu AA# 55 PEGylated interferon beta 1a 55 ALN VSP Phase 55 severe hypercholesterolemia 55 farletuzumab 55 Phase IIa Clinical Trial 55 pharmacodynamics 55 Initiates Phase II 55 octreotide implant 55 multicenter trials 55 LIALDA 55 Endovascular Valve Edge 55 abiraterone acetate 55 registrational trials 55 Ventavis 55 CLIRS trial 55 lead Aganocide compound 55 metastatic castrate resistant 55 ORMD 55 Genasense ® 55 Ceflatonin ® 55 sodium glucose cotransporter 55 generation NNRTI